Skip to main content

and
  1. No Access

    Article

    Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

    Human leukocyte antigen (HLA)-B has been recognized as a major determinant of discrepancies in disease outcomes, and recent evidence indicates a role in immune checkpoint blockade (ICB) efficacy. The B44 super...

    Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu, Tristan Grogan in Nature Cancer (2020)